Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Halozyme Therapeutics (HALO) Stock Is Absurdly Cheap Right Now

Artisan Mid Cap Fund recently released its Q1 2020 Investor Letter, a copy of which you can download below. The fund posted a return of -11.55% for the quarter (investor class), outperforming their benchmark, the Russell Midcap Index which returned -27.07% in the same quarter. You should check out Artisan Mid Cap Fund’s top 5 stock picks which helped them beat the market by nearly 16 percentage points. There weren’t a lot of funds who could deliver these kinds of returns without shorting the market or using aggressive put options.

In the said letter, Artisan Mid Cap Fund highlighted a few stocks and Halozyme Therapeutics Inc. (NASDAQ:HALO) is one of them. Halozyme Therapeutics is a biotechnology company based in California. Year-to-date, HALO stock gained 36.2% and on May 8th it had a closing price of $23.61. Its market cap is of $3.33 billion. Here is what Artisan Mid Cap Fund said:

“Halozyme is a biotechnology firm that licenses to pharmaceutical companies the use of its proprietary enzyme—its ENHANZE® platform—which aids delivery of biologics subcutaneously, as opposed to intravenously. The benefit is improved absorption and convenience to patients and physicians. The company has established partnerships with leading biopharma companies—Roche, Johnson and Johnson (JNJ), Bristol-Myers Squibb and Argenx—and ENHANZE is already used in three approved products. A fourth approval is pending for JNJ/Genmab’s Darzalex SC, a subcutaneous treatment for multiple myeloma, which we believe will come through later this year and become a large driver of royalty revenue over time. Furthermore, the company decided in late 2019 to fully exit its highly capitalintensive drug-development business, which we believe simplifies the business, reduces the company’s exposure to binary events and should lead to significant cash flow growth and margin expansion over time. We used the recent market pullback to initiate a position at what we believe is an attractive valuation.”

In Q4 2019, the number of bullish hedge fund positions on HALO stock decreased by about 4% from the previous quarter (see the chart here), so various other hedge fund managers don’t seem to agree with HALO’s growth potential. Notably, Halozyme has established a partnership with leading biopharma company Johnson & Johnson (NYSE:JNJ) for the use of ENHANZE.

Disclosure: None. This article is originally published at Insider Monkey.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.